Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program.

Omadacycline was tested against 21,000 bacterial isolates collected prospectively from medical centers in Europe and the United States during 2016. Omadacycline was active against Staphylococcus aureus (MIC50 /MIC90 , 0.12/0.25 mg/liter), including methicillin-resistant S. aureus (MRSA); streptococci (MIC50 /MIC90 , 0.06/0.12 mg/liter), including Streptococcus pneumoniae , viridans group streptococci, and beta-hemolytic streptococci; Enterobacteriaceae , including Escherichia coli (MIC50 /MIC90 , 0.5/2 mg/liter); Haemophilus influenzae (MIC50 /MIC90 , 1/1 mg/liter); and Moraxella catarrhalis (MIC50 /MIC90 , 0.25/0.25 mg/liter). Omadacycline merits further study in serious infections where resistant pathogens may be encountered.